-transparent.png){kind=logo}
The therapeutic activity of a single 2 g dose of secnidazole was studied in patients with urogenital trichomoniasis. In 140 patients, 97% were cured and the drug was well tolerated. In the laboratory, tests on sensitivity were made and the minimal inhibitory concentration (MIC) and the minimal trichomonacidal concentration (MTC) were determined on cultures that had recently been isolated at the clinic, and the pharmacokinetic properties of secnidazole in man were compared with those of tinidazole. The therapeutic efficacy of all the metronidazole derivatives was reviewed and a single-dose treatment is recommended. Therapeutic and prophylactic treatment is achieved by products with a long half-life. Secnidazole, with a half-life of 14.3 +/- 1.3 h (women) and 20.2 +/- 3.1 h (men), is particularly suitable for this type of treatment.
D Videau, and
G Niel, and
A Siboulet, and
F Catalan
July 1979,
The Journal of antimicrobial chemotherapy,
D Videau, and
G Niel, and
A Siboulet, and
F Catalan
April 2023,
Sexually transmitted diseases,
D Videau, and
G Niel, and
A Siboulet, and
F Catalan
January 1974,
Pharmaceutica acta Helvetiae,
D Videau, and
G Niel, and
A Siboulet, and
F Catalan
January 1974,
Pharmaceutica acta Helvetiae,
D Videau, and
G Niel, and
A Siboulet, and
F Catalan
March 1975,
Canadian Medical Association journal,
D Videau, and
G Niel, and
A Siboulet, and
F Catalan
August 2015,
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
D Videau, and
G Niel, and
A Siboulet, and
F Catalan
December 2020,
Drug research,
D Videau, and
G Niel, and
A Siboulet, and
F Catalan
October 2008,
The Journal of pharmacy and pharmacology,
D Videau, and
G Niel, and
A Siboulet, and
F Catalan
May 1986,
Antimicrobial agents and chemotherapy,
D Videau, and
G Niel, and
A Siboulet, and
F Catalan
April 1978,
Experientia,
